

NCT01322464 comparison:

Summary:
CHIA has 22 criteria while your personal folder has 22 criteria
Total found criteria: 22/22
Total not Found: 0/22
Total Extra: 3
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Healthy males between 18 and 45 years of age       │ Healthy males between 18 and 45 years of age       │
│ (inclusive)                                        │ (inclusive)                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Body mass index to be between 18 to 30 kg/m2       │ Body mass index to be between 18 to 30 kg/m2       │
│ (inclusive) as calculated by weight(Kg)/height(m2) │ (inclusive) as calculated by weight(Kg)/height(m2) │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects were to have no clinically significant    │ Subjects were to have no clinically significant    │
│ abnormal findings on physical examination, ECG,    │ abnormal findings on physical examination, ECG,    │
│ medical history, or clinical laboratory results    │ medical history, or clinical laboratory results    │
│ during screening                                   │ during screening                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects were to, in the opinion of the            │ Subjects were to, in the opinion of the            │
│ investigator, have no clinically significant       │ investigator, have no clinically significant       │
│ abnormal findings of renal and hepatic function as │ abnormal findings of renal and hepatic function as │
│ determined by serum creatinine, total bilirubin,   │ determined by serum creatinine, total bilirubin,   │
│ and transaminase levels                            │ and transaminase levels                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects were to be non-users of tobacco products  │ Subjects were to be non-users of tobacco products  │
│ (minimum of 6 months prior to the start of the     │ (minimum of 6 months prior to the start of the     │
│ study)                                             │ study)                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects were to have a negative screen for HIV I  │ Subjects were to have a negative screen for HIV I  │
│ and II, HBsAg, and antibody to Hepatitis C virus   │ and II, HBsAg, and antibody to Hepatitis C virus   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects were to have a negative urine screen for  │ Subjects were to have a negative urine screen for  │
│ alcohol, drugs of abuse (screening only), and      │ alcohol, drugs of abuse (screening only), and      │
│ cotinine                                           │ cotinine                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects were to use an appropriate barrier method │ Subjects were to use an appropriate barrier method │
│ of contraception (condom and spermicide) in        │ of contraception (condom and spermicide) in        │
│ addition to having their female partner use        │ addition to having their female partner use        │
│ another form of barrier contraception (e.g.female  │ another form of barrier contraception (e.g.female  │
│ condom or occlusive cap with spermicide) during    │ condom or occlusive cap with spermicide) during    │
│ the study and for 3 months following               │ the study and for 3 months following               │
│ administration of the study drug                   │ administration of the study drug                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects were able to comply with the protocol and │ Subjects were able to comply with the protocol and │
│ the restrictions and assessments therein           │ the restrictions and assessments therein           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects were to give voluntary written informed   │ Subjects were to give voluntary written informed   │
│ consent to participate in the trial                │ consent to participate in the trial                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects were not to have a history or presence of │ Subjects were not to have a history or presence of │
│ significant cardiovascular, pulmonary, hepatic,    │ significant cardiovascular, pulmonary, hepatic,    │
│ renal, haematologic, gastrointestinal, endocrine,  │ renal, haematologic, gastrointestinal, endocrine,  │
│ immunologic, dermatologic, neurologic, or          │ immunologic, dermatologic, neurologic, or          │
│ psychiatric disease                                │ psychiatric disease                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects were not to have any history or presence  │ Subjects were not to have any history or presence  │
│ or family history of schizophrenia, other          │ or family history of schizophrenia, other          │
│ psychotic illness, severe personality disorder,    │ psychotic illness, severe personality disorder,    │
│ depression, or other significant psychiatric       │ depression, or other significant psychiatric       │
│ disorder                                           │ disorder                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects were not to have a postural drop of 20    │ Subjects were not to have a postural drop of 20    │
│ mmHg or more in systolic blood pressure at         │ mmHg or more in systolic blood pressure at         │
│ screening                                          │ screening                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects were not to have participated in a        │ Subjects were not to have participated in a        │
│ previous clinical trial within 90 days prior to    │ previous clinical trial within 90 days prior to    │
│ study initiation                                   │ study initiation                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects were not to have donated plasma within 90 │ Subjects were not to have donated plasma within 90 │
│ days prior to study initiation                     │ days prior to study initiation                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects were not to have donated blood within 90  │ Subjects were not to have donated blood within 90  │
│ days prior to study initiation                     │ days prior to study initiation                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects were not to have had an abnormal diet or  │ Subjects were not to have had an abnormal diet or  │
│ substantial changes in eating habits within 30     │ substantial changes in eating habits within 30     │
│ days prior to study initiation                     │ days prior to study initiation                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects were not to have had treatment with any   │ Subjects were not to have had treatment with any   │
│ known enzyme-altering agents (barbiturates,        │ known enzyme-altering agents (barbiturates,        │
│ phenothiazines, cimetidine etc.) within 30 days    │ phenothiazines, cimetidine etc.) within 30 days    │
│ prior to or during the study                       │ prior to or during the study                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects were to have no history of known          │ Subjects were to have no history of known          │
│ hypersensitivity or idiosyncratic reaction to the  │ hypersensitivity or idiosyncratic reaction to the  │
│ study drug or related compounds                    │ study drug or related compounds                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects were not to use any prescription          │ Subjects were not to use any prescription          │
│ medication within 14 days prior to or during the   │ medication within 14 days prior to or during the   │
│ study                                              │ study                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects were not to use any over-the-counter      │ Subjects were not to use any over-the-counter      │
│ medication within 7 days prior to or during the    │ medication within 7 days prior to or during the    │
│ study                                              │ study                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects were not to have a history of alcohol or  │ Subjects were not to have a history of alcohol or  │
│ drug abuse within 2 years prior to the study       │ drug abuse within 2 years prior to the study       │
│ (subjects with a history of previous use of        │ (subjects with a history of previous use of        │
│ cannabis were not excluded unless they had used    │ cannabis were not excluded unless they had used    │
│ cannabis or cannabinoid based medicine within 30   │ cannabis or cannabinoid based medicine within 30   │
│ days prior to study drug administration or were    │ days prior to study drug administration or were    │
│ unwilling to abstain for the duration of the       │ unwilling to abstain for the duration of the       │
│ study)                                             │ study)                                             │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have minimum age of 18 Years │
├───────────────────────────────────┤
│ Must have maximum age of 45 Years │
├───────────────────────────────────┤
│ Must be MALE                      │
╘═══════════════════════════════════╛